Evidence map›Paper›PMID 27604616›Full record

ArticleInternational journal of hematology2016

Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.

Yusuke Koizumi, Tomoko Uehira, Yasunori Ota, Yoshihiko Ogawa, Keishiro Yajima, Junko Tanuma, Mihoko Yotsumoto, Shotaro Hagiwara, Satoshi Ikegaya, Dai Watanabe and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Sinonasal Plasmablastic Lymphoma: A Systematic Review.Journal of neurological surgery reports · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Plasmablastic lymphoma: current perspectives.Blood and lymphatic cancer : targets and therapy · 2018
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yusuke KoizumiDepartment of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan. ykoizumi@aichi-med-u.ac.jp.
Tomoko UehiraDepartment of Infectious Diseases, Osaka National Hospital, Osaka, Osaka, Japan.
Yasunori OtaDepartment of Pathology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Yoshihiko OgawaDepartment of Infectious Diseases, Osaka National Hospital, Osaka, Osaka, Japan.
Keishiro YajimaDepartment of Infectious Diseases, Osaka National Hospital, Osaka, Osaka, Japan.
Junko TanumaAIDS Clinical Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Mihoko YotsumotoDepartment of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan.
Shotaro HagiwaraDepartment of Hematology, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Satoshi IkegayaDepartment of Hematology and Oncology, University of Fukui Hospital, Fukui, Fukui, Japan.
Dai WatanabeDepartment of Infectious Diseases, Osaka National Hospital, Osaka, Osaka, Japan.
Hitoshi MinamiguchiDepartment of Hematology, Shiga University of Medical Science, Otsu, Shiga, Japan.
Keiko HodoharaDepartment of Hematology, Shiga University of Medical Science, Otsu, Shiga, Japan.
Kenta MurotaniDivision of Biostatistics, Clinical Research Center, Aichi Medical University, Nagakute, Aichi, Japan.
Hiroshige MikamoDepartment of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Hideho WadaDepartment of Hematology, Kawasaki Medical School, Kawasaki, Okayama, Japan.
Atsushi AjisawaDepartment of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Takuma ShirasakaDepartment of Infectious Diseases, Osaka National Hospital, Osaka, Osaka, Japan.
Hirokazu NagaiDepartment of Hematology, Nagoya Medical Center, Nagoya, Aichi, Japan.
Yoshinori KodamaDepartment of Pathology, Osaka National Hospital, Osaka, Osaka, Japan.
Tsunekazu HishimaDepartment of Pathology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Makoto MochizukiDepartment of Pathology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
Harutaka KatanoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Seiji OkadaCenter for AIDS Research, Kumamoto University, Kumamoto, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmablastic lymphoma (PBL) is a rare AIDS-related malignancy with a poor prognosis. Little is known about this entity, and no standard treatment regimen has been defined. To establish an adequate treatment strategy, we investigated 24 cases of PBL arising in human immunodeficiency virus-positive individuals. Most of the patients were in the AIDS stage, with a median CD4 count of 67.5/µL. Lymph nodes (58 %), gastrointestinal tract (42 %), bone marrow (39 %), oral cavity (38 %), and CNS (18 %) were the most commonly involved sites. Histology findings for the following were positive at varying rates, as follows: CD10 (56 %); CD30 (39 %); CD38 (87 %); MUM-1 (91 %); CD138 (79 %); EBER (91 %); and LMP-1 (18 %). There was a marked increase in patients in 2011-12, and the cases found in that period appeared to be more aggressive, showing a higher rate of advanced-stage PBL. Fourteen cases were treated with CHOP, while the others were treated with more intensive regimens, including bortezomib and hematopoietic stem cell transplantation. The overall median survival time was 15 months. A CD4 count of >100/µL at diagnosis and attaining complete remission in the first-line chemotherapy were associated with better outcomes (P = 0.027 and 0.0016, respectively). Host immune status and chemosensitivity are associated with improved prognosis in PBL.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsAnti-Retroviral AgentsCD4 Lymphocyte CountCyclophosphamideDoxorubicinEpstein-Barr Virus InfectionsFemaleHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHIVHumansLymphoma, AIDS-RelatedMaleMiddle AgedPlasmablastic LymphomaAnti-Retroviral AgentsCyclophosphamideDoxorubicinPrednisoneVincristineAcquired immunodeficiency syndromeCD4Combination antiretroviral therapyEpstein–Barr virusHuman immunodeficiency virusPlasmablastic lymphoma

Identifiers

PMID27604616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.